Pfizer, Valneva say EMA validates Lyme vaccine marketing application
Reuters2026/08/14 05:00- Pfizer, Valneva Lyme vaccine candidate PF-07307405 marketing application validated by the EMA, triggering the start of the agency’s review.
- Filing backed by Phase 3 VALOR data showing more than 70% efficacy in people aged 5 and older; no safety concerns identified.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
